In order to use adenovirus (Ad) type 5 (Ad5) for cancer gene therapy, Ad needs to be de-targeted from its native receptors and re-targeted to a tumor antigen. A limiting factor for this has been to find a ligand that (i) binds a relevant target, (ii) is able to fold correctly in the reducing environment of the cytoplasm and (iii) when incorporated at an optimal position on the virion results in a virus with a low physical particle to plaque-forming units ratio to diminish the viral load to be administered to a future patient. Here, we present a solution to these problems by producing a genetically re-targeted Ad with a tandem repeat of the HER2/neu reactive Affibody molecule (ZH) in the HI-loop of a Coxsackie B virus and Ad receptor (CAR) binding ablated fiber genetically modified to contain sequences for flexible linkers between the ZH and the knob sequences. ZH is an Affibody molecule specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) that is overexpressed in inter alia breast and ovarian carcinomas. The virus presented here exhibits near wild-type growth characteristics, infects cells via HER2/neu instead of CAR and represents an important step toward the development of genetically re-targeted adenoviruses with clinical relevance.
Introduction
The capacity of vectors to deliver genes to specific cells is crucial for in vivo gene therapy. Most of the viruses that are candidates for gene therapy vectors have a broad tissue tropism and infect many different cell types, which limit their use and safety for systemic administration. In addition, the receptor for the most common Adenovirus (Ad) receptor is downregulated in many tumor cells.
Ad have been shown to be useful vectors for gene transfer as they show high transduction efficiency and are biologically safe. 1 At the cellular level, the attachment of Ad type 5 (Ad5) is mediated by binding of the trimeric fiber protein to cellular receptors: Coxsackie B virus and Ad receptor (CAR) 2 or heparan sulfate glycosaminoglycans (HS-GAG).
3 Internalization of the virion is then mediated by the binding of RGD motifs in the penton base to cell surface integrins avb3 and avb5. 4 In order to be useful as an in vivo gene therapy vector, Ad requires re-targeting to new cellular receptors (transductional re-targeting) as well as de-targeting from normal tissue receptors. 5 De-targeting of Ad requires at least three steps: (i) ablation of the natural binding of the fiber knob to the CAR receptor, 6 which can be achieved by point mutations in the sequences responsible for CARbinding [7] [8] [9] or by generation of de-knobbed fibers; [10] [11] [12] [13] [14] (ii) removal of the KKTK motif in the third shaft repeat in the fiber that seems to be responsible for the HS-GAG binding 15 that mediates liver uptake and (iii) mutation of the integrin-binding motifs in the penton base to lower unwanted uptake in normal tissues. 16 Transductional retargeting can be achieved by the use of bispecific reagents, chemical coupling of ligands to the virion or by genetic fusion of a suitable ligand with a viral capsid protein. 17 A new cell-binding ligand incorporated genetically into Ad vectors must fold correctly in the mammalian cell cytoplasm where the virus proteins are synthesized before they are transported to the nucleus for virus assembly. 11 This fact excludes most of the ligands dependent on disulfide bond formation for proper folding, such as the epidermal growth factor and most single-chain variable fragments. 11 We have previously shown that a class of ligands based on a three a-helical bundle structure, that is, the so-called Affibody molecules, can be efficiently used for genetic re-targeting of Ad. 12 Affibody molecules are combinatorially engineered ligands based on a 58 amino-acid domainderived from Staphylococcal protein A (SpA). 18, 19 Affibody variants can be selected for binding to desired targets using phage display technology.
The choice of genetic fusion partner on the Ad capsid for the new cell-binding ligand is likely to be of major importance as manipulation of virus capsid proteins affects the virus phenotype. Previous results have shown that viable re-targeted Ad5 can be constructed by genetically removing the knob, shortening the shaft and introducing the neck-region peptide from human lung surfactant D as a new trimerization motif, followed by a new cell-binding ligand. 10 However, it has been demonstrated that recombinant adenovirus with modified capsid proteins are difficult to produce to wild-type titers, and exhibits poor growth characteristics. 10, 12 The poor performance of viruses with de-knobbed fibers is due to the fact that the knob has other important functions in the life cycle of the virus than just binding to the cellular receptor. [20] [21] [22] [23] [24] [25] These facts make such viruses difficult to use for gene therapeutic purposes.
The HI-loop of the fiber knob, however, possesses a number of features that makes it suitable for ligand incorporation: it consists mostly of hydrophilic amino acids, and is exposed on the outside of the knob, demonstrating a high flexibility. Studies have shown that the HI-loop tolerates insertion of various linear peptides up to 111 amino acids, [26] [27] [28] a fact that makes it a potential site for insertion of Affibody molecules.
A solution to the problems described above is offered in this investigation, and resides in the construction of viruses with Affibody ligands, incorporated with flanking flexible linkers into the HI-loop of CAR ablated fiber knobs. The rationale behind this strategy is that the flexible linkers may allow for correct and independent folding of the adjacent knob domain sequences as well as the new ligand peptide sequence. By allowing for correct folding of the knob sequences, it is suggested that knob functions important to virus replication will be retained.
The ZH is an Affibody molecule that binds the extracellular domain of HER2/neu (HER2/neu, also called ErbB2), belonging to the tyrosine kinase receptor family, and is associated with increased proliferation and decreased apoptotic capacity. [29] [30] [31] A dimeric variant of the ZH has been found to bind Her2/neu with 3 nM affinity.
32 HER2/neu is overexpressed in different cancers, above all breast and ovarian. 33 As an example, a subgroup of 25-30% of all breast cancers overexpress this receptor, 34 and are thus possible targets for gene therapy. In Europe, almost 2.9 million incident cases of cancer were diagnosed in 2004, and 12.8% of these were breast cancer. In the same year, 129 900 patients died from this disease. 35 In this study, a head-to-tail dimer of the ZH Affibody molecule was genetically inserted into the fiber knob HI-loop, modified to provide extra polypeptide linkers between ZH and knob sequences. As a comparison, a similar fiber without the polypeptide linkers and a short de-knobbed fiber was made. In order to remove the CAR binding from the HI-loop fibers, two amino acids were deleted in the knob. It is shown that, by using this strategy, it is indeed possible to generate viable virions with new cell-binding specificity and most importantly, the HI-loop virus with polypeptide linkers exhibits close to wild-type characteristics in growth rate. It is also shown that the integrin-binding motif in the penton base of the ZH-targeted virus can be mutated and that the resulting virus still infects HER2/neu-expressing cells. This is a large step forward, as compared to other strategies, for genetic incorporation of new cell-binding ligands into Ad. As the virus with ZHZH in the HI-Linkloop is already deleted for CAR-binding, this accomplishes the first and most important step toward a powerful cancer gene therapy vector for breast and ovarian cancers.
Materials and methods

Cells
HEK-293 cells (abbreviated 293 cells) were purchased from Microbix (Toronto, Ontario, Canada). Spodoptera frugiperda (Sf9), human ovarian carcinoma cells (SKOV-3) cells, human breast cancer (SKBR-3) cells and rhabdomyosarcoma (RD) cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). 293, SKOV-3, SKBR-3 and RD cells were grown in Iscoves medium (Gibco BRL, Invitrogen Life Technologies, Groningen, The Netherlands), supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, Stockholm, Sweden) and 50 mg/ml gentamycin (Gibco BRL). 293-Fb cells 20 were kindly provided from Transgene and cultivated in Dulbecco's modified Eagle's medium containing 4.5 g glucose/l (Gibco BRL) and supplemented with 10% FBS (Gibco BRL) and 350 mg/ml hygromycin B (Boehringer, Mannheim, Germany). All cells were maintained at 371C and 5% CO 2 .
Sf9 cells were grown in TC100 medium (Gibco BRL) with the above-mentioned supplements at 281C. 293 HER2/neu cells are HEK-293 cells stably transfected for surface expression of HER2/neu. The gene encoding the complete gene of HER2/neu was amplified by polymerase chain reaction (PCR) from human breast tumor cDNA using primers introducing a NotI and a HindIII restriction enzyme cleavage site, respectively. The HER2/neu gene was cloned into the pcDNA3.1 vector (Invitrogen, Groningen, The Netherlands) with NotI and HindIII. The gene fragment encoding the complete HER2/neu gene in pcDNA3.1 was used to transfect 293 cells in passage 30-32 and G418-resistant foci were isolated, expanded and stained for HER2/neu expression. 293 HER2/neu cells were cultured in Iscoves medium (Gibco BRL), supplemented with 10% FBS (SigmaAldrich, Stockholm, Sweden) and 400 mg/ml G418 (Gibco BRL) and maintained at 371C and 5% CO 2 .
Immuno reagents
Mouse monoclonal antibody (mAb) 4D2.5 (anti-Ad5 fiber tail) 36 was kindly provided by Dr Jeffery Engler, University of Alabama, Birmingham, AL. Rabbit-antipenton base polyclonal Ab was laboratory made. Anti-CAR antibody was produced from the RmcB mouse myeloma cell line from ATCC (CRL-2379). fluorescein isothiocyanate (FITC)-conjugated antimouse immunoglobulin (Ig)G rabbit F(ab) 2 (F0313), AP-conjugated goat antirabbit-IgG (D0487) and FITC-conjugated rabbit antihuman IgG (F0315) were purchased from DAKO (Glostrup, Denmark). AP-conjugated goat antimouseIgG (A2179) was purchased from Sigma-Aldrich. Anti-HER2/neu Herceptin (humanized mIgG1) was from Roche (Basel, Switzerland) and HER2-ECD (HER2/neu Extra Cellular Domain) from Fox Chase Cancer Center (Philadelphia). 37 Affinity purified His6-(ZH) 2 Affibody molecule was produced as described in Wikman M et al.
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Ad5 knob and FibDCAR-HI-Link-SpA domain (Zwt) were expressed in Sf9 cells, the cells were lysed and the concentrations of knob and fiber in the soluble fractions were measured by Western blot in comparison with a purified-fiber protein with known concentration.
Targeting ligands
Affibody molecules are based on the noncystein threehelix bundle structure of a modified Z wt . 18, 19 Through combinatorial protein engineering targeted to surface located residues of the Z wt domain, libraries have been constructed from which novel variants have been selected. 19, 38 The Affibody molecule used in this study is the ZH, specific for the ECD of HER2/neu. 30 Generation of recombinant truncated knobless fibers Recombinant fibers containing the native fiber tail and the first seven shaft repeats, followed by an external trimerization motif from lung surfactant protein D (neck region peptide (NRP)), 39 a linker from SpA and monomeric or dimeric versions of ZH as a new cellular ligand, were constructed and evaluated as previously described. [10] [11] [12] A schematic representation of the constructed recombinant Ad5 fibers studied is shown in Figure 1 . Recombinant fibers were designated R7, followed by the name of the new ligand/s (Figure 1b) .
Construction of recombinant fiber genes with 13-shaft repeats Shaft repeat 8-13 was amplified by PCR using the primers 5 0 -GGA AAG CTA GCC CTG CAA ACA-3 0 (5 0 -primer) and 5 0 CAG GGC TAG CTT GCC TTG TGA ATC AAA ACC CAA-3 0 (3 0 -primer, 13th repeat). The shaft parts were then ligated into R7-knob fiber using the NheI site at the seventh shaft repeat, giving rise to fiber R13-knob. The 13 shaft repeats and NRP from R13-knob were digested with NdeI/ClaI and ligated to R7-ZH and R7-ZHZH fibers to give R13-ZH and R13-ZHZH ( Figure 1c ).
Generation of CAR ablated fibers carrying the Affibody ZH in the HI-loop of the fiber knob To construct FibDCAR-HI-ZH, the sequence CCA TCG ATC containing a ClaI restriction site was inserted into the HI-loop of the Ad5 WT fiber between the GGA (amino acid G541) and GAC (amino acid D542) using splicing by overlap extension. The same sequence was introduced at the 3 0 and 5 0 ends of the Affibody ZH nucleotide sequence by means of PCR. The Affibody was then ligated into the new ClaI site in the HI-loop of the fiber. Ablation of the CAR-binding site was constructed through deletion of residues Leu 485 and In order to allow for constructs where linkers containing the amino acids Gly and Ser are introduced on either side of the Affibody molecule (Figure 1e and f), the following adapter was ligated into the ClaI site described above: CGA TCG GTT CTG GTG GTG GTT CTA GAG GAT CCG GCG GCT CCG GTG GTC CAT. The adapter contains XbaI and BamHI sites (underlined) for ligation of Affibody molecule sequences. The corresponding site sequences were introduced into Affibody molecules by PCR. Splicing by overlap extension was used to create a dimeric Affibody molecule with a flexible (G 4 S) 2 linker between the ZH domains (GGC GGC GGT GGT TCT GGT GGT GGC GGC TCC).
Phenotypic analysis of fiber proteins
Ad5 WT fiber and recombinant (R7-, R13-and FibD CAR-HI-) fibers were cloned into the pBacPak9 vector (Clontech, Palo Alto, CA). Recombinant baculoviruses (Autographa californica Nuclear Polyhedrosis Virus, AcNPV) were generated by homologous recombination in Sf9 cells using the BacVector-1000 DNA Kit, as described by the manufacturer (Novagen, Madison, WI). Fiber proteins were expressed in Sf9 cells infected with recombinant baculoviruses and analyzed according to the following criteria: (i) solubility; (ii) trimerization; (iii) ligand reactivity by cellular binding; and (iv) ligand reactivity by biosensor analyses. Solubility (i) and trimerization (ii) assays of proteins expressed with recombinant baculovirus have been described previously. 10 Reactivity of ligands on recombinant fibers. The reactivity of ZH ligands genetically introduced into Ad fibers was analyzed by a cell-binding assay with or without blocking by affinity-purified His6-(ZH) 2 Affibody molecules. 32 Baculovirus-infected Sf9 cells were harvested 48 h post-infection (pi), lysed in hypotonic buffer (10 mM Tris-HCl buffer, pH 7.5) at 01C, adjusted to isotonic conditions (150 mM NaCl in10 mM Tris-HCl buffer, pH 7.5) and centrifuged at 10 000 g, 41C, for 10 min. For the cell-binding assay the fiber containing supernatants were applied to cells in suspension (293 and SKOV-3) prewashed in phosphate-buffered saline (PBS) (0.01 M phosphate, 0.15 M NaCl). After washing the cells, they were incubated with antibody 4D2.5 and washed in PBS, followed by incubation with fluorescein isothiocyanateconjugated rabbit antimouse Igs. Negative controls with supernatants from uninfected Sf9 cells were performed. FITC-labeled cells were counted using fluorescent-activated cell sorter (FACS) (FACSsort, Becton Dickinson, Heidelberg, Germany), as previously described. 10 The blocking experiment was performed as described above, but with incubation of the cells with 0-100 mg/ml His6-(ZH) 2 prior addition of the fiber supernatants. All steps were performed at 41C.
Cell surface expression of HER2/neu and CAR was analyzed by staining the cells as described above, but using 10 mg/ml Herceptin or RmcB-anti-CAR antibody, followed by FITC-labeled antihuman-IgG or antimouseIgG, respectively.
Biosensor analyses of recombinant fibers. A BIAcore 2000 instrument (Biacore AB, Uppsala, Sweden) was used for real-time biospecific interaction analysis (BIA) between recombinant fiber constructs with ZH Affibody ligands, and the target protein. HER2-ECD (diluted in 10 mM NaAc, pH 4.5) was immobilized (B2600 RU) on the carboxylated dextran layer of one flow-cell surface of a CM5 sensor chip (research grade) (BR-1000-14, Biacore) by amine coupling, according to the manufacturer's instructions. Another flow-cell surface was activated and deactivated to be used as a reference surface, and human IgG (Amersham Biosciences, GE Healthcare Biosciences, Uppsala, Sweden) was immobilized on the CM5 sensor chip, to serve as negative control. The recombinant fiber cell lysate samples were diluted in HBS-EP (5 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 150 mM NaCl, 3.4 mM ethylenediaminetetraacetic acid, 0.005% surfactant P20, pH 7.4) and the samples were filtrated (0.45 mm; Millipore, Billerica, MA). Binding analyses were performed at 251C with HBS-EP as running buffer. The fiber samples were injected over all surfaces with a flow rate of 20 ml/min and run in duplicates. As negative control, two unrelated Affibodyliganded fibers were used.
Rescue of recombinant fibers into virions
The Ad5/WT-fiber gene was replaced by the FibR7-ZH, FibR7-ZHZH, FibR13-ZH, FibR13-ZHZH, FibDCAR-HI-ZH, FibDCAR-HI-Link-ZH and FibDCAR-HI-Link-ZHZH fibers, respectively, in the Ad5 genome, using a previously described procedure based on homologous recombination and cosmid cloning. 10 In the resulting recombinant Ad5 genome, the E1 region was replaced with the green fluorescent protein (GFP) gene under a cytomegalovirus promoter. FibDCAR-HI-Link-ZHZH was also cloned into an Ad genome carrying a penton base with EGD instead of RGD. 40 PCR amplification and DNA sequencing verified the presence of a correct fiber and penton base insert with the expected sequence. The cosmid was also controlled by cleavage with HindIII and SpeI. Recombinant Ad5 genomes were restricted with PacI and used to transfect 293 HER2/neu cells using the FuGene technology and the manufacturer's protocol (Roche). The occurrence of plaques was determined by microscopic inspection of the transfected cell cultures. Presence of viruses was verified by PCR and GFP expression. Viruses were purified from infected cells by freeze thawing followed by cesium chloride (CsCl) gradient. All virus stocks were titered on 293 HER2/neu cells by end-point dilution, and the titer expressed as plaque-forming units (PFU)/ml 41 and the number of viral particles/ml was determined by optical absorbance. 42 FibDCAR-HI-ZH was rescued by transfection into fiber complementing cells (293-Fb cells), followed by a second infection into 293 cells to give virus with the recombinant fiber alone.
Individual plaques were photographed on day 4 pi in a Nikon Eclipse TS100 microscope ( Â 20 magnification) using a Nikon Coolpix9900 camera.
Fiber content of recombinant Ad5 virions
The fiber copy number of CsCl-purified Ad5 virions was determined using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. Blots were reacted with anti-tail mAb 4D2.5, followed by AP-conjugated anti-mouse IgG or rabbitanti-penton base polyclonal Ab, followed by mouse-antirabbit-AP to assay the fiber versus penton content. Quantification was performed using the ImageJ program (http://rsb.info.nih.gov/ij/).
Growth rate of recombinant Ad
Growth rate was measured by the production of PFU in infected cells. 293 HER2/neu cells were infected with 20 PFU/cell of Ad5/FibDCAR-HI-Link-ZHZH, Ad5/ EGD/FibDCAR-HI-Link-ZHZH or Ad5/FibWT at 371C in Iscoves. After 1 h, the cells were washed and 1 ml complete medium (Iscoves with 10% FBS and 50 mg/ml gentamycin) was added. Cells and medium were harvested 25, 48 and 72 h pi. After cell lysis by freezethawing, the number of infectious virions in the lysates was determined on 293 HER2/neu cells by end-point dilution, and the recombinant virus yield was expressed as PFU/cell.
Gene transfer assays
The re-targeting of Ad5/FibDCAR-HI-Link-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH, as compared to Ad5/FibWT, was studied by gene transfer of GFP to different cell types. Infections were performed in 24-well plates for 1 h at 371C in 200 ml complete Iscoves. Blocking was performed by adding 1 mg/ml Ad5 knob, 5 mg/ml FibDCAR-HI-Link-Zwt or 100 mg/ml His6-(ZH) 2 to the cells for 1 h at 37, 37 and 41C, respectively, after which the virus was added and the incubation continued at 371C for 1 h. After infection, cells were washed once in complete Iscoves and kept in medium with the same supplements overnight at 371C. After approximately 15-20 h, the cells were harvested, fixed with 0.5% glutaraldehyde for 15 min and washed with PBS. GFP-expressing cells were counted using FACS (FACSsort, Becton Dickinson, Heidelberg, Germany), as previously described. 10 
Results
Construction of recombinant ZH-liganded fibers
In order to re-target Ad5 to the tumor antigen HER2/neu and simultaneously remove CAR-binding, two different approaches were evaluated: (i) to remove the knob and replace it by an external trimerization signal and the ZH ligand and (ii) to insert ZH in the HI loop of a fiber with a deleted CAR-binding site. A variety of fibers were made with ZH in monomer or tandem repeats, knobless fibers with seven or 13 shaft repeats and ligation into the HIloop with or without linker sequences. Schematic pictures of the different capsid proteins used in the study are shown in Figure 1 .
Recombinant Ad5 fibers carrying the tail, seven or 13 shaft repeats, an external trimerization motif and a linker (SpA), followed by ZH Affibody as monomer or tandem repeat, were designated R7 or R13 followed by the name of the new ligand, that is, FibR7-ZHZH and FibR13-ZHZH (Figure 1b and c) . The ZH inserted as a monomer into the sequence of the HI-loop of a CAR ablated Ad5 fiber was named FibDCAR-HI-ZH (Figure 1d) . Furthermore, linkers were introduced on either side of the ZH in the HI-loop constructs to generate FibDCAR-HI-Link-ZH and FibDCAR-HI-Link-ZHZH (Figure 1e and f) . To name recombinant viruses, the prefix Ad5 was added as in Ad5/FibR7-ZHZH.
Phenotypic analysis of ZH recombinant fibers
To examine the properties of the different fibers, they were expressed in the cytoplasm of Sf9 insect cells using the baculovirus expression system and analyzed according to the following criteria: (i) solubility, (ii) trimerization, (iii) ligand reactivity by cellular binding and (iv) ligand reactivity as measured by receptor interaction measured in vitro by plasmon resonance biosensor analyses (BIAcore). Results shown below are from studies of FibDCAR-HILink-ZHZH, but the fibers in Figure 1b -e all showed a similar pattern.
Solubility. In a previous study, 11 it was demonstrated that the solubility of recombinant fibers expressed in the cytoplasm of Sf9 cells is a reliable criterion of their proper folding and ability to yield viable viruses. Accordingly, the new fiber proteins were produced in the baculovirusinsect cell system. The solubility status was tested by electrophoresis and Western blotting of Sf9 cell lysates denatured by boiling in SDS (SDS-PAGE). The supernatant (soluble fraction) was compared to centrifuged pellet (insoluble fraction). All recombinant fibers had close to equal solubility as compared to the WT fiber (data not shown).
Trimerization. For fibers to anchor to the penton base, they must form homotrimers and, therefore, the trimerization status was tested by electrophoresis and Western blotting of Sf9 expressed fiber samples in non-denaturing SDS-PAGE (NDS-PAGE). 10 For all recombinant fibers of this study, a pattern similar to WT was observed, showing that they were all able to form trimers (data not shown), which is in agreement with previous results with similarly constructed fibers. 10, 12, 40 Ligand reactivity by binding to cellular receptors. After having established the solubility and trimerization status of the fiber, the ligand reactivity was analyzed by cellbinding assay. Recombinant fibers from baculovirusinfected Sf9 cells were applied to 293 and SKOV-3 cells (Figure 2 To further prove the specificity of the ZH liganded fibers, an affinity-purified dimeric version of ZH (His6-(ZH) 2 ) was used to block the binding of fibers to cells. The WT fiber showed no difference in mean fluorescent intensity, whereas FibDCAR-HI-Link-ZHZH was totally blocked using 100 mg/ml His6-(ZH) 2 prior addition of the fibers (Figure 3 ). Both fibers were also blocked by an anti-knob antibody that blocks the transducing ability of WT virus (data not shown). As the FibDCAR-HI-Link-ZHZH fiber does not bind to CAR, it would be reasonable to suggest that the anti-knob antibody effect in this case was caused by a steric hindrance, as has been reported for alternative Ad5 receptors before. 43 Taken together, these results suggest that the recombinant fibers were specific with respect to their inserted Her2 Affibody, and that deletion of CAR and the insertion of the Affibody molecule ZH did not introduce any unwantedbinding properties.
Ligand reactivity measured by BIAcore. To further secure that the ZH liganded fibers really bound to the aimed target receptor, the fibers expressed in Sf9 cells were analyzed for HER2-ECD binding by real-time BIA with a BIAcore biosensor instrument. The fiber samples were diluted in running buffer, and subsequently injected over separate sensor chipflow-cell surfaces containing the immobilized target protein HER2-ECD or the control protein IgG. The FibDCAR-HI-Link-ZHZH construct showed specific binding to HER2-ECD ( Figure 4 ). As expected, no binding to the control protein IgG could be seen (Figure 4 ). Neither could binding be seen for the two negative control Affibody containing fiber samples to the HER2-ECD surface (data not shown).
Rescue into virions and phenotype of recombinant virions
To construct virus with the recombinant re-and detargeted fibers, the WT fiber gene was replaced by the different fibers in the Ad5 genome using a previously described procedure based on homologous recombination and cosmid cloning. 10 To construct a control virus, the WT fiber was inserted using the same method, resulting in a virus with a capsid indistinguishable from WT Ad. 10 All viruses were made to express the GFP in E1 for convenient detection of infection. The FibDCAR-HILink-ZHZH was also cloned into an Ad genome with an amino-acid substitution in the penton base (RGD to EGD) to abolish binding to integrins. 40 To be able to separate the viruses, they were named Ad5/FibDCAR-HILink-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH. Recombinant Ad genomes were transfected into 293 HER2/neu cells, and plaques were observed for FibD CAR-HI-Link-ZHZH containing viruses after 7-9 days (equal to the WT virus) and for FibDCAR-HI-Link-ZH after 11 days (Table 1) . A difference in plaque morphologies 4 days pi was detected where the DCAR-HILink-ZHZH viruses showed slightly smaller plaques as compared to WT ( Figure 5 ). FibDCAR-HI-ZH and fibers with R7 and R13 failed to give plaques on 293 HER2/neu cells, but were with some difficulty rescued on 293-Fb cells expressing the WT fiber in trans. 20 Based on these results, the Ad5/FibDCAR-HI-Link-ZHZH was chosen for further studies.
To be able to compare the viruses, physical particles (PP)/ml and plaque-forming units (PFU)/ml were determined by optical absorbance and end-point dilution, respectively. The production of PP in the recombinant viruses was two times lower as compared to the WT, showing that there were no major defects in viral production ( Table 1 ). Ad5/FibDCAR-HI-Link-ZHZH was found to have a PP-to-PFU ratio of 140 compared to 70 for WT, whereas the ratio for Ad5/EGD/FibDCAR-HI-Link-ZHZH was 2200 ( Table 1) .
The number of fiber copies per virion for Ad5/ FibDCAR-HI-Link-ZHZH, Ad5/EGD/FibDCAR-HI-Link-ZHZH and Ad5/FibWT were compared in CsCl-purified Figure 4 Biosensor-binding studies. Sensorgram obtained after injection of FibDCAR-HI-Link-ZHZH over sensor chip flow-cell surfaces containing amine-coupled HER2-ECD (black squares) or human IgG (white squares). Samples were run at 251C in duplicates, and the response obtained from an activated and deactivated reference surface has been subtracted from all curves. virus samples ( Figure 6 and Table 1 ). Equal numbers of PP were analyzed and probed for penton base and fiber tail. Protein analysis showed that when the amount of penton base was normalized, the Ad5/FibDCAR-HILink-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH had fiber contents of 25 and 12% as compared to Ad5/ FibWT ( Figure 6 ). Repeated analysis of fiber content for two different preparations of Ad5/FibDCAR-HI-Link-ZHZH compared to Ad5/FibWT gave results of similar quantity (24-29%). FibDCAR-HI-ZH, which was rescued on 293-Fb cells, had a fiber content of approximately 25% (data not shown).
Growth rate and cellular specificity of recombinant virus The growth rate of Ad5/FibDCAR-HI-Link-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH was determined by measurement of the infectious progeny yields (titered by plaque assays on 293 HER2/neu cells) and compared to Ad5/ FibWT ( Figure 7 ). The growth curves of the DCAR-HIlinkZHZH containing viruses suggest that they are slower in production of infectious particles, and at 48 h pi find a steady state of about one log less than Ad5/FibWT. The specificity of the recombinant viruses and Ad5/ FibWT was first tested by gene transfer and expression of GFP to 293 and 293 HER2/neu cells (Figure 8a) , where it was shown that the WT virus infects both cell lines at almost equal efficiency, whereas the FibDCAR-HI-Link-ZHZH viruses have a specificity for 293 HER2/neu cells. To assay if the binding to 293 HER2/neu cells was mediated by the HER2/neu tumor antigen, a competition assay using knob protein or purified His6-(ZH) 2 Affibody was performed. Results showed that the WT virus was blocked only by the knob protein and the ZH-targeted Figure 6 Representative Western blot showing fiber content of purified virus. 4 Â 10 9 PP of CsCl-purified Ad virions were analyzed by SDS-PAGE and Western blot using a-penton base and a-fiber tail antibodies, followed by AP-conjugated anti-rabbit or anti-mouse antibodies, respectively. Measurements of fiber loads were made by the ImageJ program. 2 Affibody. Cells were infected with Ad5/FibWT, Ad5/FibDCAR-HI-Link-ZHZH and Ad5/EGD/FibD CAR-HI-Link-ZHZH at 10 and 50 PFU/cell for 1 h at 371C, with or without prior incubation with 1 mg/ml knob or 100 mg/ml His6-(ZH) 2 Affibody for 1 h at 371C and 41C, respectively. Cells were harvested at 16-20 h pi, and the percentage of GFP-expressing cells were determined by FACS (m7s.d., n ¼ 3).
viruses by His6-(ZH) 2 (Figure 8a and b) . As a control for the knob blocking, the FibDCAR-HI-Link-Zwt protein was used at 5 mg/ml without any effect on infectivity (data not shown).
Next step was to study gene transfer to breast and ovarian cancer cells, and for this purpose the cell lines SKOV-3 and SKBR-3 were used. SKOV-3 cells express HER2/neu and almost no CAR (Figure 2) , and SKBR-3 cells express both HER2/neu and CAR (data not shown). The RD cells, which were used as a negative control, do not express CAR and probably express a defective HER2/neu as they bind Herceptin but do not bind ZH liganded fibers (data not shown). The receptor for ZH is, therefore, lacking. It is known that ZH and Herceptin do not bind to the same epitope on the HER2/neu antigen as they cannot block each other. 30 In concordance with this hypothesis, Ad5/FibDCAR-HI-Link-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH could be shown to poorly infect RD cells but to infect SKOV-3 and SKBR-3 cells well compared to WT ( Figure 9 ).
Discussion
The present study demonstrates that it is possible to construct genetically re-targeted Ad with close to WT growth characteristics if one uses ligands that can fold correctly in the cytoplasm of the infected cells and take measures that allow for correct folding of knob sequences adjacent to the new cell-binding ligand. As a vast majority of Affibody molecules show the same folding and stability characteristics, the technology described should be considered a platform technology for this particular type of ligand. Certainly, there is no fiber construct that is universal for all possible ligands, and when using other ligands alternative fiber constructs might have to be used.
We have previously shown that there is a restraint on complex nonlinear ligands to be used for genetic retargeting of Ad; that is, the ligands must be able to fold correctly and preserve their receptor binding in the reducing environment of the mammalian cell cytoplasm.
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In an earlier publication, we showed that the so-called Affibody molecules, 19 based on a partially randomized three-a´-helix bundle scaffold, are stable in the cytoplasm and can be successfully used to create genetically retargeted adenoviruses. 12 We present here the use of a Her2/neu specific Affibody molecule (ZH), genetically inserted at different positions in the adenoviral fiber for re-targeting purposes. The data presented here corroborate and extend our earlier observations 12 by demonstrating that the Affibody molecule ZH is properly expressed in the cytoplasm and can be genetically incorporated into the fibers of viable adenoviruses with retained target binding. In correspondence with the Affibody ligands that we have used before, ZH could be incorporated into knobless fibers both as a monomer and as a tandem repeat with excellent cytoplasmic solubility and antigen binding. These fibers could be incorporated into viable viruses that, however, exhibit even worse growth defects than we have previously encountered in similar Affibodyliganded viruses. 12, 40 These growth defects can be explained by a low-fiber content caused by the lack of the fiber knob hampering virus entry and intracellular trafficking and a loss of other growth -or viral assembly functions carried by the fiber knob. [20] [21] [22] [23] [24] [25] Only in the de-knobbed virus Ad5/R7-C2C2, containing the Ig binding C2 domain from Streptococcal protein G, we found a normal fiber content indicating that this fiber somehow compensates, as far as fiber content of the virus is concerned, for the loss of the fiber knob. 40 Therefore, a novel approach was also employed in the present study. The Affibody molecules were introduced into the HI-loop of the CAR ablated fiber knob using flexible linkers between upstream as well as downstream knob sequences and between the Affibody molecules. The use of linkers to allow for independent domain folding is an approach also taken in other Biotechnological areas such as the construction of immunotoxins 44 and singlechain antibody fragments. 45 The hypothesis behind the present approach was that the linkers might facilitate the independent folding of the domains involved, thereby allowing the fiber knob to preserve functions apart from receptor binding that seems to be important for Ad function. The hypothesis is supported by the fact that the best fiber by far, in terms of efficiency of the resulting virus, was the FibDCAR-HI-Link-ZHZH. The blocking of binding of these fibers by free ZH clearly demonstrates that the specificity of binding of these fibers is determined by the incorporated ZH ligand. The solubility of recombinant fibers in the cytosol of eukaryotic cells has been considered a good criterion of their gross-folding characteristics. 10, 11 All the recombinant fibers were about equally soluble when expressed in the cytoplasm of insect cells. Despite this, there was a big difference between the ability of the different fibers to be incorporated into viable viruses by transfection of viral genomes into 293 HER2/neu cells. The fiber with ZH in the linkerless HI-loop could not be rescued into virus at all in these cells, but could with some difficulty be rescued in 293-Fb cells, expressing the WT fiber in trans 20 pointing to the importance of the linker construct. Solubility on its own is therefore, not a reliable criterion for the ability of recombinant fibers to be able to be rescued into functional virus.
Subnormal fiber content is one of the factors suggested to cause slow growth in genetically re-targeted Ad, and a decreased infectivity is also observed in Ad carrying subnormal copy numbers of WT fiber. 20, 46 Other studies suggest that an intact fiber knob is necessary for a normal fiber content. 47 In addition to cellular binding, the fiber and its knob domain have been suggested to carry several functions important for intracellular trafficking, membrane lysis and virus maturation. [20] [21] [22] [23] [24] [25] Fiber content of FibDCAR-HI-Link-ZHZH viruses was 12-29% of WT, which is an improvement from earlier studies where knobless virions have had fiber content of 2-10%. 10 Another improvement of Ad5/FibDCAR-HI-Link-ZHZH was the PP-to-PFU ratio, which was 140, as compared to 70 for the WT virus. This, closeness to the WT ratio might be due to the presence of the knob domain as, in a previous study, two knobless viruses, Ad5/FibR7-Z wt Z wt and Ad5/FibR7-C2C2, were found to have PP/PFU ratios of 4100 and 16 000, respectively. 40 This ratio is of importance as it affects the total amount of virions that will need to be injected into a patient in a future clinical setting. A large difference was detected in the PP/PFU ratio between RGD and EGD containing viruses, 140 and 2200, respectively, indicating that the EGD mutation has implications for the virus, although it still readily infects cells expressing HER2/neu.
In view of the somewhat subnormal phenotypic characteristics of the FibDCAR-HI-Link-ZHZH virus described above, it seems that knob functions may still be compromised to a certain degree in this virus. It should be considered that the linker construct described here might be further optimized using a random phage display library to pull out even more effective linkers than the one described. This approach has proven fruitful in the case of single chain antibody fragments. 45 As the HI-loop-linker construct described above gave superior virus performance, the FibDCAR-HI-Link-ZHZH viruses were used for plaque formation, growth rate and gene-transfer studies. The morphology of plaques was similar, but slightly smaller for FibDCAR-HI-Link-ZHZH containing viruses, compared to WT at 4 days pi; however, this only delayed the spread of the virus in the monolayer by 1 day. Ad5/FibDCAR-HI-Link-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH were shown to have a growth rate of about one log less than WT, which is an improvement from our previous studies using knobless viruses. 10, 12 We could also demonstrate virus specificity for the HER2/neu antigen as virus entry could be blocked by free ZH Affibody, but not by free-knob protein. Ad5/FibDCAR-HI-Link-ZHZH and Ad5/EGD/FibDCAR-HI-Link-ZHZH were shown to infect 293 HER2/neu , SKBR-3 and, to a lower level, SKOV-3 cells. No infection of RD cells could be demonstrated. The RD cells were included in this study because they do not express CAR or the ZH receptor. The RD cell data thus show that there was no unwanted binding to a cell line without the proper receptors. As shown in the competition assay, the two ZHZH-targeted viruses (RGD and EGD) could be blocked by His6-(ZH) 2 Affibody. This shows that (i) the FibDCAR-HI-Link-ZHZH viruses infect cells via HER2/neu; (ii) RGDdependent integrins are not needed for internalization of the virus and (iii) the virus with EGD infects cells as readily as the virus with WT penton base. This will be important in vivo in order to diminish unwanted binding by the RGD motif, but still not to hamper targeting abilities. For successful targeting, endocytosis is required for delivery of the agent into the interior of the cell. Selfefficient internalization of antibodies against Her2/neu has been described both for trastuzumab (Herceptin) [48] [49] [50] and F5. 51 Other receptors that are known to induce internalization are the EGF 52 and transferrin receptors. 53 Direct selection of internalizing antibodies can be made from phage display libraries, as not all antibodies against a selected target will promote internalization. 54 No studies have been made to distinguish between internalization and natural receptor recycling pathways for the ZH Affibody. It is most likely that, the binding to Her2/neu promotes receptor internalization as it has been shown that about 30% of the monovalent ZH and 50% of the bivalent ZHZH are internalized after binding to SKBR-3 cells at all measured time points between 0-24 h. 32 It can also be assumed that internalization into endosomes can be stimulated if the virus, with its multivalent ZH ligands, pulls together several Her2/neu antigens, as multi-valency or bi-valency is often needed for internalization of antibodies. A somewhat contradicting result has been published by us earlier, when targeting by binding of the Herceptin antibody to the Ad5/R7-C2C2 virus needed RGD in the penton base to be able to infect HER2/neuexpressing cells. 40 This discrepancy may be explained both by the fact that the C2C2-targeted virus is a knobless virus, whereas the virus described above is likely to retain several knob functions, and that the C2C2 virus uses indirect targeting by an antibody bound to the virus.
It is worth noting that the ZHZH tandem-repeat linker HI-loop construct was more effective than the ZH monomer variant. The reason is not clear. The tandem repeat fiber is a larger construct and would be expected to have a more deleterious impact on the ability of neighboring knob domains to fold correctly. However, this may be counteracted by the linker added between the Affibody molecules. The tandem repeat also has a higher avidity for HER2/neu than the monomer. 32 However, the affinity of the monomeric ZH is already in the nanomolar range, 30 which is comparable to the affinity of the WT knob for CAR (3 nM). 55 By trying to allow for correct folding of the knob sequence and by choosing a ligand that can fold correctly in the cytoplasm of infected cells, we have been able to produce a re-targeted Ad with improved phenotype and a new specificity with clinical relevance. Hopefully, the stabile and robust framework of Affibody molecules will make this a platform technology, and targets other than HER2/neu can be employed. We also hope that the rationale behind the strategy presented here can be of use for targeting of Ads with ligands other than Affibody molecules.
